Audiologists in St Paul, MN Accepting Medicare

5 Audiologists found. Showing 1 - 5

Linda Ellen Murrans, MA CCC A Audiologist Medicare: Not Enrolled in Medicare Practice Location: 345 North Smith Avenue, Childrens Hospitals And Clinics Audiology St Paul, St Paul, MN 55102 Phone: 651-220-6880

Mrs. Kim Marie Austin, MS CCCA Audiologist Medicare: Not Enrolled in Medicare Practice Location: 393 N Dunlap, #115, St Paul, MN 55104 Phone: 651-646-2427    Fax: 651-649-3018

Leah Nichole Tygum, AUD CCCA Audiologist Medicare: Medicare Enrolled Practice Location: 345 North Smith Avenue, Childrens Hospitals And Clinics Audiology St Paul, St Paul, MN 55102 Phone: 651-220-6880

Mrs. Sarah Judith Kahley, AUD CCCA Audiologist Medicare: Not Enrolled in Medicare Practice Location: 393 N Dunlap St, 600, St Paul, MN 55104 Phone: 651-645-0691    Fax: 651-603-8100

Judith Lynn Davison, AU.D. Audiologist Medicare: Accepting Medicare Assignments Practice Location: 393 N Dunlap St, #600, St Paul, MN 55104 Phone: 651-645-0691    Fax: 651-603-8100

News Archive

Kaiser Permanente's California mental health clinicians to launch week-long strike on January 12

Kaiser Permanente's 2,600 California mental health clinicians — psychologists, therapists, and social workers represented by the National Union of Healthcare Workers — will launch a statewide, week-long strike on Monday, January 12, to protest Kaiser's chronic failure to provide its members with timely, quality mental health care.

Loyola oncologist named ‘Heroes of Hope' by Leukemia Research Foundation

The Leukemia Research Foundation has named Loyola University Medical Center oncologist Dr. Tulio Rodriguez one of its "Heroes for Hope."

Breakthrough research allows scientists to program cells like computers for battling against diseases

Cells can be programmed like a computer to fight cancer, influenza, and other serious conditions - thanks to a breakthrough in synthetic biology by the University of Warwick.

FDA grants orphan drug status to Reata's pancreatic cancer drug

Reata Pharmaceuticals, Inc. has announced that RTA 402 has been granted orphan drug designation by the U.S. Food and Drug Administration (FDA) for the treatment of pancreatic cancer. RTA 402 is currently being studied in a Phase 1/2 trial in patients with pancreatic cancer, and is also in Phase 2 development for chronic kidney disease.

Read more Medical News

› Verified 7 days ago